Land: Holland
Sprog: hollandsk
Kilde: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
TENOFOVIRDISOPROXIL
Hetero Europe S.L.
J05AF07
TENOFOVIRDISOPROXIL
Filmomhulde tablet
CELLULOSE, MICROKRISTALLIJN (E 460) ; CROSPOVIDON (E 1202) ; HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464) ; LACTOSE 1-WATER ; MACROGOL 400 ; MAGNESIUMSTEARAAT (E 470b) ; MAÏSZETMEEL, GEPREGELATINEERD ; POLYSORBAAT 80 (E 433) ; TITAANDIOXIDE (E 171),
Oraal gebruik
Tenofovir Disoproxil
Hulpstoffen: CELLULOSE, MICROKRISTALLIJN (E 460); CROSPOVIDON (E 1202); HYPROMELLOSE, Type 2910 (3 - 15 mPa.s) (E 464); LACTOSE 1-WATER; MACROGOL 400; MAGNESIUMSTEARAAT (E 470b); MAÏSZETMEEL, GEPREGELATINEERD; POLYSORBAAT 80 (E 433); TITAANDIOXIDE (E 171);
2017-04-24
Tenofovir disoproxil Hetero 245 mg filmomhulde tabletten, 245 mg, film-coated tablet – NL/H/3598/001/DC NL pl NL/p/007/17/5 1 PACKAGE LEAFLET: INFORMATION FOR THE USER TENOFOVIR DISOPROXIL HETERO 245 MG FILMOMHULDE TABLETTEN tenofovir disoproxil READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Tenofovir disoproxil Hetero is and what it is used for 2. What you need to know before you take Tenofovir disoproxil Hetero 3. How to take Tenofovir disoproxil Hetero 4. Possible side effects 5. How to store Tenofovir disoproxil Hetero 6. Contents of the pack and other information IF TENOFOVIR DISOPROXIL HETERO HAS BEEN PRESCRIBED FOR YOUR CHILD, PLEASE NOTE THAT ALL THE INFORMATION IN THIS LEAFLET IS ADDRESSED TO YOUR CHILD (IN THIS CASE PLEASE READ “YOUR CHILD” INSTEAD OF “YOU”). 1. WHAT TENOFOVIR DISOPROXIL HETERO IS AND WHAT IT IS USED FOR Tenofovir disoproxil Hetero contains the active substance _tenofovir disoproxil_. This active substance is an _antiretroviral _or antiviral medicine which is used to treat HIV or HBV infection or both. Tenofovir is a nucleotide _reverse transcriptase inhibitor_, generally known as an NRTI and works by interfering with the normal working of enzymes (in HIV _reverse transcriptase_; in hepatitis B _DNA _ _polymerase_) that are essential for the viruses to reproduce themselves. In HIV Tenofovir disoproxil Hetero should always be used combined with other medicines to treat HIV infection. TENOFOVIR DISOPROXIL HETERO 245 MG FILM-COATED TABLETS ARE A TREATMENT FOR H Læs hele dokumentet
Tenofovir disoproxil Hetero 245 mg filmomhulde tabletten, 245 mg, film-coated tablet – NL/H/3598/001/DC NL SmPC NL/s/004/17/3 1 1. NAME OF THE MEDICINAL PRODUCT Tenofovir disoproxil Hetero 245 mg filmomhulde tabletten _ _ 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 245 mg of tenofovir disoproxil. Excipient(s) with known effect: Each tablet contains 232 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. White coloured, almond shaped, biconvex film-coated tablets with a dimension of approx. 16 mm in length and 10 mm in width, debossed with “H” on one side and “T11” on the other side. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS _HIV-1 infection _ Tenofovir disoproxil Hetero 245 mg film-coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults. In adults, the demonstration of the benefit of Tenofovir disoproxil Hetero in HIV-1 infection is based on results of one study in treatment-naïve patients, including patients with a high viral load (>100,000 copies/ml) and studies in which Tenofovir disoproxil Hetero was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (<10,000 copies/ml, with the majority of patients having <5,000 copies/ml). Tenofovir disoproxil Hetero 245 mg film-coated tablets are also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to <18 years. The choice of Tenofovir disoproxil Hetero to treat antiretroviral-experienced patients with HIV-1 infection should be based on individual viral resistance testing and/or treatment history of patients. _Hepatitis B infection _ Tenofovir disoproxil Hetero 245 mg film-coated tablets are indicated for the treatment of chronic hepatitis B in adults with: compensated liver disease, with evidence of ac Læs hele dokumentet